Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager

爱尔康（SIX/NYSE: ALC），全球眼科护理领域的领导者，致力于帮助人们获得清晰视力，今天宣布Voyager在美国全面商业化上市。

DSLT, the first and only Direct Selective Laser Trabeculoplasty device (DSLT). Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking the treatment’s availability for more patients. Designed for an exceptional patient and physician experience, Voyager DSLT is fully automated—efficiently delivering 120 laser pulses without the need for a gonio lens as with manual SLT..

DSLT，首个且唯一的直接选择性激光小梁成形术设备（DSLT）。Voyager DSLT 独具优势，能够加速激光作为一线治疗手段的普及，为更多患者提供这种治疗选择。Voyager DSLT 专为卓越的患者和医生体验而设计，完全自动化，无需手动SLT所需的前房镜即可高效传递120个激光脉冲。

Attendees of the 2025 American Glaucoma Society (AGS) meeting in Washington, D.C., from February 26 through March 2, will be able to experience Voyager DSLT first-hand at the Alcon booth (#29-32) and during the launch event (registration is available:

2025年2月26日至3月2日，在华盛顿特区举行的美国青光眼学会（AGS）会议的与会者将能够在爱尔康展位（#29-32）以及发布会活动（注册现已开放：

“I have been using Voyager DSLT since October of 2024, and it has made an incredible impact on the use of SLT for my practice,” said Inder Paul Singh, MD, President of The Eye Centers of Racine and Kenosha. “My patients have been delighted by the efficiency, comfort level of the treatment, and overall experience.

“自2024年10月以来，我一直在使用Voyager DSLT，它对我的实践中使用SLT产生了令人难以置信的影响，”拉辛和基诺沙眼科中心的总裁Inder Paul Singh医学博士说道，“我的患者对治疗的效率、舒适度以及整体体验感到非常满意。”

Voyager DSLT has been embraced by my staff and is easy to implement, allowing me to treat more of my patients with a recognized first-line standard in glaucoma treatment.”.

“Voyager DSLT 已被我的员工接受，且易于实施，使我能够以公认的青光眼治疗一线标准治疗更多的患者。”

Glaucoma is a progressive disease that impacts millions of people around the world. In the U.S. alone, the number of glaucoma patients is expected to grow from 5 million to 6.3 million by 2050.

青光眼是一种影响全世界数百万人的渐进性疾病。仅在美国，青光眼患者数量预计到2050年将从500万增长到630万。

Glaucoma is the leading cause of irreversible blindness globally, with many unaware that they have glaucoma until the disease has progressed to vision loss. Due to its progressive nature, early intervention and a variety of treatment options—from drops to surgical intervention—is critical to preserve sight..

青光眼是全球不可逆失明的主要原因，许多人在青光眼发展到视力丧失之前并不知道自己患有此病。由于其进展性，早期干预和多种治疗选择（从滴眼液到手术干预）对于保护视力至关重要。

Notable medical societies, including the American Academy of Ophthalmology and others from around the world, recognize SLT as an effective first-line therapy.

包括美国眼科学会和世界各地的其他著名医学协会都认可SLT作为一种有效的首选治疗方法。

However, practical challenges, such as the duration of treatment and specialized training necessary to perform manual SLT, have limited its accessibility for many doctors and the patients who would otherwise benefit from it.

然而，治疗时间长短和实施手动SLT所需的专业培训等实际挑战，限制了许多医生及其原本可从中受益的患者的可及性。

“Alcon is dedicated to developing treatments and technologies for people living with glaucoma,” said Terry Kim, MD, Chief Medical Officer and Head of Global Medical Safety, Alcon. “By introducing Voyager DSLT, we’re able to broaden access to first-line SLT therapy and provide Eye Care Professionals with crucial early intervention for their glaucoma patients.”.

“爱尔康致力于为青光眼患者开发治疗方案和技术，”爱尔康首席医疗官兼全球医疗安全主管Terry Kim博士说道。“通过推出Voyager DSLT，我们能够扩大一线SLT治疗的可及性，并为眼科保健专业人士提供对其青光眼患者至关重要的早期干预手段。”

Voyager DSLT is controlled through an intuitive touchscreen, taking the slit lamp and manual gonio lens aiming out of the equation, and reduces the specialized training required with manual SLT.

Voyager DSLT 通过直观的触摸屏进行控制，无需使用裂隙灯和手动Gonio镜瞄准，并减少了手动SLT所需的专业培训。

Voyager DSLT offers precise delivery, powered by SureTrac™ eye-tracking technology, to accurately and safely deliver laser pulses through the limbus to the trabecular meshwork, stimulating the eye's natural healing response to improve aqueous outflow.

Voyager DSLT 通过 SureTrac™ 眼动追踪技术提供精准的激光脉冲传输，能够准确且安全地通过角膜缘将激光传递至小梁网，刺激眼睛的自然愈合反应以改善房水流出。

Additionally, in a survey of 24 physicians who experienced a DSLT demo, 96% agreed they would want to be offered first-line DSLT if they were patients.

此外，在对24名经历过DSLT演示的医生进行的调查中，96%的医生表示如果他们是患者，他们希望被提供一线DSLT治疗。

A randomized, controlled trial has shown that DSLT delivers effective intraocular pressure (IOP) control and has a strong safety profile with low risk of adverse events.

一项随机对照试验表明，DSLT能够有效控制眼内压（IOP），并且具有良好的安全性，不良事件风险低。

The data and early feedback demonstrate:

数据和早期反馈表明：

Nearly 2 out of 3 (62%) DSLT participants were medication-free at 12 months.

将近三分之二（62%）的DSLT参与者在12个月时已无需用药。

After 6 months, nearly all DSLT patients indicated they would recommend the treatment to a friend with glaucoma.

6个月后，几乎所有的DSLT患者都表示会将该治疗推荐给患有青光眼的朋友。

The benefits of DSLT position laser therapy to become a more widespread first-line intervention for glaucoma patients.

DSLT 激光治疗的优势使其有望成为青光眼患者更广泛使用的一线干预措施。

Voyager DSLT will be available for demo and purchase at AGS 2025 in Washington, D.C., at the Alcon booth (#29-32). AGS attendees can also learn more at the “Unlock First-line Glaucoma Care: Voyager™ DSLT” launch symposium, in the Diamond Theatre (Palladian Room) on February 27 at 7:15 a.m. EST. Register .

Voyager DSLT 将在华盛顿特区举行的2025年AGS大会上的Alcon展位（#29-32）进行展示和销售。AGS参会者还可以在2月27日东部时间早上7:15于钻石剧院（Palladian Room）举行的“解锁一线青光眼护理：Voyager™ DSLT”发布研讨会中了解更多信息。注册 。

About Alcon

关于爱尔康

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors.

爱尔康帮助人们清晰视物。作为拥有75年以上历史的眼科护理全球领导者，我们提供最广泛的产品组合来增强视力并改善人们的生活。我们的外科和视力保健产品每年惠及140多个国家中超过2.6亿受白内障、青光眼、视网膜疾病和屈光不正等问题困扰的人们。

Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at .

我们的两万五千多名员工通过创新的产品、与眼科护理专业人士的合作以及推动获得优质眼科护理的项目，提升了人们的生活质量。欲了解更多信息，请访问。

About Voyager™ DSLT

关于Voyager™ DSLT

Indications / Intended Use:

适应症/预期用途：

The Direct Selective Laser Trabeculoplasty (DSLT) device is an ophthalmic laser device designed for performing selective laser trabeculoplasty. It is an automated device for direct selective laser trabeculoplasty (DSLT) that employs a Q‒switched, 3‒ns pulse width, frequency-doubled Nd: YAG laser of wavelength 532 nm.

直接选择性激光小梁成形术（DSLT）设备是一种用于进行选择性激光小梁成形术的眼科激光设备。它是一种自动化的直接选择性激光小梁成形术（DSLT）设备，采用波长为532纳米的Q开关、3纳秒脉宽、倍频Nd:YAG激光。

It directs the 400‒μm diameter laser beam to the eye limbus region without any contact with the patient's eye. An image-processing algorithm automatically locates the target area on the limbus, which the operator or Eye Care Professional (ECP) adjusts as necessary. After the operator confirms the limbus target, an eye-tracking algorithm tracks eye movement so that the laser pulses are delivered accurately to the targeted location on the limbus.

它将直径为400微米的激光束引导至角膜缘区域，且不与患者的眼睛接触。一种图像处理算法自动定位角膜缘上的目标区域，操作员或眼科保健专业人员（ECP）可根据需要进行调整。操作员确认角膜缘目标后，眼球追踪算法会追踪眼球运动，以确保激光脉冲准确传递到角膜缘上的目标位置。